The clinical-stage biopharma just can't catch a break from Wall Street.
News & Analysis: Bellicum Pharmaceuticals
Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner?
The biopharma announced first-quarter 2018 results and provided an update on the business.
Bellicum Pharmaceuticals may appear like a bargain, but a deeper dive suggests otherwise.
The biopharma announced a public offering of common stock.
Bellicum Pharmaceuticals' lead product candidate is back on track. Should investors buy this news?
Both biotechs are developing next generation gene therapies, but only one company is a clear cut buy.
Enthusiasm for this biotech is at an all-time low. Has the market pushed the stock into bargain territory?
A major clinical setback is wrecking havoc on Bellicum's share price today.
Bellicum may disappoint investors yet again in 2018. Here's why.